title: Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
abstract: Mouse leukemia L1210 cells were generated for resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ), a potent inhibitor of ribonucleotide reductase that is directed in the nonheme iron subunit (NHI) of the enzyme. The resistant cells, MQ-580, showed an 8-fold increase in IC50 toward MAIQ, a 4-fold increase in IC50 toward hydroxyurea, and also showed resistance to other ribonucleotide reductase inhibitors. In addition, the MQ-580 cell line was resistant to nonribonucleotide reductase inhibitors such as etoposide, daunomycin and vinblastine, but not to cisplatin. The mRNA for the NHI subunit was increased 7-fold in the MQ-580 cells with essentially no change in the mRNA level for the effector-binding subunit. The ribonucleotide reductase activity in the cell-free extracts prepared from the MQ-580 cells was only slightly elevated (30%). However, passage of the cell-free extract from the MQ-580 cells over Sephadex G-25 resulted in a 4.8-fold increase in specific activity over that of the wild-type cells. While the reductase activity in the cell-free extract from the MQ-580 cells did not show altered sensitivity to MAIQ, the reductase activity in the cell-free extract from the MQ-580 cells was much more sensitive to the effects of the iron-chelating agents Desferal and EDTA. The cell pellets from the MQ-580 cells were much darker in color than the pellets from the wild-type cells or hydroxyurea-resistant cells. The supernatant fraction from the MQ-580 cells after-SDS-PAGE showed the appearance of a strong Coomassie blue-staining band at 50 kDA that was not apparent in either the wild-type or hydroxyurea-resistant cells. This new resistant cell line offers an opportunity to explore differences in resistance mechanisms of drugs (e.g. MAIQ and hydroxyurea) that are directed at the same subunit of ribonucleotide reductase.
authors.affiliation: Department of Biochemistry, East Carolina University School of Medicine, Greenville, NC 27858, USA.
authors.forename: A H
authors.initials: AH
authors.lastname: Cory
authors.forename: A
authors.initials: A
authors.lastname: Sato
authors.forename: D P
authors.initials: DP
authors.lastname: Thompson
authors.forename: J G
authors.initials: JG
authors.lastname: Cory
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology*; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D046911:Macromolecular Substances; D051379:Mice; D012333:RNA, Messenger / Q000378:metabolism; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007546:Isoquinolines; D046911:Macromolecular Substances; D012333:RNA, Messenger; C013118:4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone; D012264:Ribonucleotide Reductases